https://leerink.com/articles/ 2026-06-24T19:02:35+00:00 https://leerink.com/article/turning-the-page-on-a-challenging-year-for-healthcare-equities-and-looking-ahead-to-2024/ 2024-07-10T13:45:32+00:00 https://leerink.com/wp-content/uploads/2024/05/LP-Article-Hero-Image_Healthcare-Equities_01-1.jpg https://leerink.com/wp-content/uploads/2024/05/Leerink-Chart-Healthcare_1100px@2x.jpg https://leerink.com/wp-content/uploads/2024/05/Leerink-Chart-Annual-Healthcare_RF04@2x.jpg https://leerink.com/wp-content/uploads/2024/05/Leerink-Chart-XBI-Long-Term-Treasuries_1100px@2x-1024x682-1.png https://leerink.com/wp-content/uploads/2024/05/Case-Study-Haves-HaveNots-SMID-Cap_03@2x-1024x804-1.png https://leerink.com/wp-content/uploads/2024/05/Leerink-Chart_Public-Biopharma-Companies_1100px_02@2x-1024x677-1.png https://leerink.com/wp-content/uploads/2024/05/Case-Study-Haves-HaveNots-XHS@2x-1024x651-1.png https://leerink.com/wp-content/uploads/2024/05/Leerink-Chart_Strong-Margins_1100px_02@2x-1024x660-1.png https://leerink.com/wp-content/uploads/2024/05/Leerink-Higher-for-Longer-Bets_1100px_03@2x-1024x717-1.png https://leerink.com/article/biopharma-ma-market-update-and-2024-outlook/ 2024-07-10T13:46:46+00:00 https://leerink.com/wp-content/uploads/2024/05/Biopharma-MA-Market-Update-2024-Hero-Image_03-1.jpg https://leerink.com/wp-content/uploads/2024/05/LP-Chart-01-HEALTHCARE-MA-ACTIVITY_04@2x.jpg https://leerink.com/wp-content/uploads/2024/05/LP-Chart-02-4Q-2023-HEALTHCARE-MA-ACTIVITY-03@2x.jpg https://leerink.com/wp-content/uploads/2024/05/LP-Chart-03-4Q-2023-BIOPHARMA-MA-ACTIVITY-New@2x-4.png https://leerink.com/wp-content/uploads/2024/05/LP-Chart-04-BIOPHARMA-Q4-SELECTED-KEY-UPCOMING-EVENTS-03@2x.jpg https://leerink.com/article/navigating-the-complex-terrain-healthcare-and-biotech-markets-in-q3-2023/ 2024-07-10T13:49:15+00:00 https://leerink.com/wp-content/uploads/2024/05/Article-Header-Healthcare-Biotech-1.jpg https://leerink.com/wp-content/uploads/2024/06/chart-01-market-performance@2x.jpg https://leerink.com/wp-content/uploads/2024/06/chart-02-healthcare-equity-issuance-by-quarter_sm_L@2x.png https://leerink.com/wp-content/uploads/2024/06/chart-03-performance-of-biotech-stock-YTD@2x.png https://leerink.com/wp-content/uploads/2024/06/chart-04-ownership-of-SMID-cap-biotech@2x.jpg https://leerink.com/wp-content/uploads/2024/06/chart-05-comanies-completed-crossover-rounds@2x.png https://leerink.com/wp-content/uploads/2024/05/Hot-Topics-Leading-the-Way_03@2x-1-scaled.jpg https://leerink.com/wp-content/uploads/2024/06/chart-07-performance-of-healthcare-subsectors_02@2x.png https://leerink.com/wp-content/uploads/2024/06/chart-08-ipo-issuance-across-sectors@2x.png https://leerink.com/wp-content/uploads/2024/05/Hot-Topics-Value-Based-Care@2x-scaled.jpg https://leerink.com/article/springtime-for-digital-health-its-not-always-rainbows-and-butterflies-its-compromise-that-moves-us-along/ 2024-07-10T13:50:39+00:00 https://leerink.com/wp-content/uploads/2024/05/Digital-Health-Header-Woman-looking-at-imaging-fnl2-1.jpg https://leerink.com/wp-content/uploads/2024/05/01-Stocks-Positive-Return-Chart-fnl-src.png https://leerink.com/wp-content/uploads/2024/05/02-Prioritizing-Profitability-Chart-fnl-src.png https://leerink.com/wp-content/uploads/2024/05/03-Rule-of-40-Chart-fnl-src.png https://leerink.com/wp-content/uploads/2024/05/04-Thawing-Private-Financing-fnl-src.png https://leerink.com/wp-content/uploads/2024/05/05-Matchmaking-Chart-fnl-src-02.png https://leerink.com/article/2022-a-terrible-horrible-no-good-very-bad-year-for-digital-health/ 2024-07-10T13:52:57+00:00 https://leerink.com/wp-content/uploads/2024/05/Article-03-Digital-Health-Year-3-1.jpg https://leerink.com/wp-content/uploads/2024/05/Public-Valuations-Have-Plummeted.png https://leerink.com/wp-content/uploads/2024/05/Insider-Led-Rounds.png https://leerink.com/wp-content/uploads/2024/05/Corporate-Restructurings.png https://leerink.com/wp-content/uploads/2024/05/Divestitures-to-ReFocus_02@2x-1024x550-1.png https://leerink.com/wp-content/uploads/2024/05/The-Exit-of-Public-Companies.png https://leerink.com/wp-content/uploads/2024/05/Digital-Health-and-High-Growth.png https://leerink.com/wp-content/uploads/2024/05/Cash-Rich-Strategies.png https://leerink.com/wp-content/uploads/2024/05/Venture-Captial-Dry-Powder.png https://leerink.com/article/digital-healths-dot-com-moment-peril-and-promise/ 2024-07-10T13:54:43+00:00 https://leerink.com/wp-content/uploads/2024/05/Article-01-DotCom-Moment-1.jpg https://leerink.com/wp-content/uploads/2024/05/Chart-01-1024x917-1.png https://leerink.com/wp-content/uploads/2024/05/Chart-02a-748x1024-1.png https://leerink.com/wp-content/uploads/2024/05/Chart-02b-1-713x1024-1.png https://leerink.com/wp-content/uploads/2024/05/Chart-03a-1024x786-1.png https://leerink.com/wp-content/uploads/2024/05/Chart-03b-1024x949-1.png https://leerink.com/wp-content/uploads/2024/05/Chart-04-1024x767-1.png https://leerink.com/article/insights-into-healthcare-ma-q2-2024-trends/ 2024-08-19T16:28:43+00:00 https://leerink.com/wp-content/uploads/2024/07/LP_InsightsIntoHealthcareMAQ22024Trends_Article_1320x430_HERO.jpg https://leerink.com/wp-content/uploads/2024/07/LP_MA_Trends_CHART_1_0724.jpg https://leerink.com/wp-content/uploads/2024/07/LP_MA_Trends_CHART_2_0724.jpg https://leerink.com/wp-content/uploads/2024/07/LP_MA_Trends_CHART_3_0724.jpg https://leerink.com/article/insights-into-healthcare-ma-q3-2024-trends/ 2024-10-10T17:52:49+00:00 https://leerink.com/wp-content/uploads/2024/10/LP_InsightsIntoHealthcareMAQ32024Trends_Article_1320x430_HERO.jpg https://leerink.com/wp-content/uploads/2024/10/LP_MA_Trends_CHARTS_1024-1.jpg https://leerink.com/wp-content/uploads/2024/10/LP_MA_Trends_CHARTS_1024-2.jpg https://leerink.com/wp-content/uploads/2024/10/LP_MA_Trends_CHARTS_1024-3.jpg https://leerink.com/article/empowering-womens-health-the-rise-of-investment-opportunities-in-women-and-family-healthcare/ 2024-10-14T15:41:14+00:00 https://leerink.com/wp-content/uploads/2024/05/Womens-Health-Hero-14-1.jpg https://leerink.com/wp-content/uploads/2024/05/Women-Stages-image-full-md.jpg https://leerink.com/wp-content/uploads/2024/05/Market-Opportunity-image-full-lg.jpg https://leerink.com/wp-content/uploads/2024/05/Venture-Investment-White-03-image-full-lg-1024x578-1.jpg https://leerink.com/wp-content/uploads/2024/05/Deal-Count-White-image-full-lg-888x1024-1.jpg https://leerink.com/wp-content/uploads/2024/05/Emerging-Landscape-image-full-lg.jpg https://leerink.com/wp-content/uploads/2024/05/Proven-Strategies-image-half-md_02.jpg https://leerink.com/article/analyzing-healthcare-ma-trends-q1-2024-insights/ 2024-10-30T17:54:04+00:00 https://leerink.com/wp-content/uploads/2024/04/LP_AnalyzingHealthcareMATrendsQ12024Insights_1320x430_HERO-1170x430-1.jpg https://leerink.com/wp-content/uploads/2024/10/LP_AnalyzingHealthcare_MA_Trends_CHARTS_CHART-1.jpg https://leerink.com/wp-content/uploads/2024/07/LP_AnalyzingHealthcare_MA_Trends_CHARTS_CHART-2-1.jpg https://leerink.com/wp-content/uploads/2024/10/LP_AnalyzingHealthcare_MA_Trends_CHARTS_CHART-3.jpg https://leerink.com/article/navigating-healthcare-ai-a-guide-for-private-equity-investors-2/ 2024-11-20T16:17:20+00:00 https://leerink.com/wp-content/uploads/2024/01/LP_ECM_LookingAheadTo2024_1320x430_Hero_CMP-1170x430-1.jpg https://leerink.com/article/generalized-cost-effectiveness-analysis/ 2024-12-16T15:55:58+00:00 https://leerink.com/wp-content/uploads/2024/11/CPE_HERO_1170x430.jpg https://leerink.com/article/a-cpe-exclusive-tecfidera/ 2025-03-31T16:37:55+00:00 https://leerink.com/wp-content/uploads/2025/03/CPE_TECFIDERA_HERO_1170x430.jpg https://leerink.com/article/a-cpe-exclusive-entresto/ 2025-04-29T13:13:50+00:00 https://leerink.com/wp-content/uploads/2025/04/CPE_ENTRESTO_HERO_1170x430.jpg https://leerink.com/article/a-cpe-exclusive-drug-launch-superstars-where-are-they-now/ 2025-06-27T11:00:00+00:00 https://leerink.com/wp-content/uploads/2025/06/CPE_SpecialReport_WhereAreTheyNow_HERO_1170x430.jpg https://leerink.com/article/a-cpe-exclusive-value-estimates-for-innovative-lipid-lowering-therapeutics-in-ascvd/ 2025-10-30T17:05:00+00:00 https://leerink.com/wp-content/uploads/2025/10/CPE_LipidLoweringASCVD_HERO_1170x430.jpg https://leerink.com/article/value-estimates-for-novel-non-dopaminergic-therapeutics-for-schizophrenia/ 2026-01-22T17:43:38+00:00 https://leerink.com/wp-content/uploads/2026/01/CPE_SchizophreniaNextGenTherapies-_HERO_1170x430.jpg https://leerink.com/article/economic-value-of-novel-therapeutics-for-primary-prevention-of-cardiovascular-disease/ 2026-02-09T14:33:49+00:00 https://leerink.com/wp-content/uploads/2026/02/CPE_ASCVDPrimaryPrevention-_HERO_1170x430.jpg https://leerink.com/article/pcsk9-inhibitors-cost-effective-for-primary-prevention/ 2026-02-17T17:49:26+00:00 https://leerink.com/wp-content/uploads/2026/02/CPE_ASCVDPrimaryPrevention-_HERO_1170x430.jpg https://leerink.com/article/pcsk9-inhibitors-cost-effective-for-primary-prevention-2/ 2026-02-25T20:05:57+00:00 https://leerink.com/wp-content/uploads/2025/10/CPE_LipidLoweringASCVD_HERO_1170x430.jpg https://leerink.com/article/economic-value-add-from-reducing-each-type-of-cardiovascular-event/ 2026-02-25T20:12:53+00:00 https://leerink.com/wp-content/uploads/2025/10/CPE_LipidLoweringASCVD_HERO_1170x430.jpg https://leerink.com/article/trends-in-utilization-cost-effectiveness-and-budget-impact-of-pcsk9-inhibitors/ 2026-03-05T19:28:13+00:00 https://leerink.com/wp-content/uploads/2026/02/CPE_ASCVDPrimaryPrevention-_HERO_1170x430.jpg https://leerink.com/article/value-informed-launch-price-estimates-for-disease-modifying-therapies-for-rrms/ 2026-03-19T20:05:58+00:00 https://leerink.com/wp-content/uploads/2026/03/CPE_GenericGCEAforRRMS_HERO_1170x430.jpg https://leerink.com/article/pricing-the-next-wave-value-competition-and-willingness-to-pay-in-rrms/ 2026-04-13T13:09:23+00:00 https://leerink.com/wp-content/uploads/2026/03/CPE_GenericGCEAforRRMS_HERO_1170x430.jpg https://leerink.com/article/value-informed-price-estimates-for-disease-modifying-therapies-in-primary-progressive-multiple-sclerosis/ 2026-04-28T19:26:46+00:00 https://leerink.com/wp-content/uploads/2026/03/CPE_GenericGCEAforRRMS_HERO_1170x430.jpg https://leerink.com/article/pricing-the-next-wave-value-competition-and-willingness-to-pay-in-rrms-2/ 2026-05-06T13:58:23+00:00 https://leerink.com/wp-content/uploads/2026/03/CPE_GenericGCEAforRRMS_HERO_1170x430.jpg https://leerink.com/article/pricing-the-next-wave-a-value-centric-lens-based-on-prior-market-rewards/ 2026-05-20T17:01:17+00:00 https://leerink.com/wp-content/uploads/2026/03/CPE_GenericGCEAforRRMS_HERO_1170x430.jpg https://leerink.com/article/the-price-of-lower-drug-prices/ 2026-05-22T13:19:05+00:00 https://leerink.com/article/pricing-the-next-wave-for-cvd-secondary-prevention/ 2026-06-02T14:30:37+00:00 https://leerink.com/wp-content/uploads/2026/02/CPE_ASCVDPrimaryPrevention-_HERO_1170x430.jpg https://leerink.com/article/economic-value-of-novel-therapeutics-for-chronic-obstructive-pulmonary-disease/ 2026-06-11T15:51:05+00:00 https://leerink.com/wp-content/uploads/2026/06/CPE_LUNGS_HERO_1170x430.jpg https://leerink.com/article/pricing-the-next-wave-for-copd/ 2026-06-24T19:02:35+00:00 https://leerink.com/wp-content/uploads/2026/06/CPE_LUNGS_HERO_1170x430.jpg